J&J reiterates 2025 sales goal despite looming Stelara exclusivity loss, global economic challenges
Johnson & Johnson is doubling down on a mid-decade pharma sales goal, and it’s plotting a way even as it loses exclusivity on one of its main blockbusters later this year.
Joaquin Duato — who became J&J’s CEO last year after Alex Gorsky stepped aside — repeated the company’s target for $60 billion in pharma sales revenue by 2025 in an investor call Tuesday morning.
That figure was laid out as a revenue goal for 2025 last year, when execs said on the Q3 earnings call that the target number was still possible through what J&J had in sales and in its pipeline at the time.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
